Arformoterol Tartrate Solution
Product Images NDC 60687-770

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Arformoterol Tartrate (NDC 60687-770). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

15 Mcg/2 mL Arformoterol Tartrate Inhalation Solution Pouch (15 Mcg Arformoterol Tartrate Inhalation Solution Pouch)

Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL unit-dose vial label by American Health Packaging. The label includes dosage form, strength, usage instructions for oral inhalation only, storage conditions, and contact information for ordering patient information sheets. It warns to keep out of reach of children and specifies the product is Rx only.*

FDA Label Image

15 Mcg Arformoterol Tartrate Inhalation Solution Carton 30 Ct (15 Mcg Arformoterol Tartrate Solution Carton 30ct)

Packaging label for Arformoterol Tartrate inhalation solution, 15 mcg per 2 mL, by American Health Packaging. The carton contains 30 sterile unit-dose vials, each 2 mL. Instructions note refrigeration or room temperature storage for up to 6 weeks and specify use for oral inhalation only. The label includes dosage strength, handling, and storage information.*

FDA Label Image

15 Mcg Arformoterol Tartrate Inhalation Solution Carton 60 Ct (15 Mcg Arformoterol Tartrate Solution Carton 60ct)

Arformoterol Tartrate Inhalation Solution 15 mcg/2 mL packaging label by American Health Packaging. The label states the product contains 60 sterile unit-dose vials of 2 mL each. It is for oral inhalation use only, with instructions for storage refrigerated or at room temperature for up to 6 weeks. The label highlights the strength and dosage form clearly on a white and blue background with product and labeler details.*

FDA Label Image

Figure1 Mean Change In Fev1 Over Time For Clinical Trial A At Week 0 (day 1) (Figure1.jpg)

A line graph displaying the mean change from baseline FEV1 (in liters) over 12 hours postdose, comparing placebo and 15 mcg Arformoterol Tartrate inhalation solution given twice daily. The graph shows higher FEV1 improvement over time in the Arformoterol group versus placebo.*

FDA Label Image

Figure 2 Mean Change In Fev1 Over Time For Clinical Trial A At Week 12 (Figure2)

A line graph showing mean change from baseline FEV1 (L) over 12 hours postdose comparing placebo and 15 mcg Arformoterol Tartrate Inhalation Solution BID. The graph shows greater improvement in FEV1 for the Arformoterol Tartrate group relative to placebo over the time period.*

FDA Label Image

Figure 1 (Ifu Figure1.jpg)

An instructional illustration showing a hand twisting the cap of a vial or ampule, with an arrow indicating the direction of rotation to open it. The image focuses on the opening mechanism of the vial for respiratory solution administration.*

FDA Label Image

Figure 2 (Ifu Figure2.jpg)

An instructional illustration showing a hand inserting a vial into a device labeled 'RESERVOIR,' likely demonstrating part of the preparation or loading process for a respiratory inhalation solution.*

FDA Label Image

Figure 5 (Ifu Figure5.jpg)

An illustration showing a compressor device with a connected tubing. The compressor has a knob and a rectangular display or vent. This diagram likely relates to the respiratory inhalation delivery system for Arformoterol Tartrate solution.*

FDA Label Image

Figure 6 (Ifu Figure6.jpg)

An instructional illustration showing a person holding an inhaler device near their mouth, demonstrating the correct way to use the inhalation solution. The image emphasizes the positioning of the inhaler for respiratory administration.*

FDA Label Image

Structural Formula (Structure)

Chemical structure of the active ingredient Arformoterol Tartrate, showing its molecular components and arrangement.*

FDA Label Image

Figures 3 And 4 (Image 01)

Illustrations showing two components of a respiratory inhalation device for Arformoterol Tartrate solution: a mouthpiece attachment and a face mask attachment. Both components are labeled and depicted separately next to the main inhalation device body.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.